COVID-19 and Thrombosis Predisposition

1. Driggin E, Madhavan MV, Bikdeli B, et al. Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic. J Am Coll Cardiol. 2020;75:2352-2371.10.1016/j.jacc.2020.03.031719885632201335Search in Google Scholar

2. Guarner J. Three Emerging Coronaviruses in Two Decades. Am J Clin Pathol. 2020;153:420-421.10.1093/ajcp/aqaa029710969732053148Search in Google Scholar

3. Sardu C, Gambardella J, Morelli MB, Wang X, Marfella R, Santulli G. Hypertension, Thrombosis, Kidney Failure, and Diabetes: Is COVID-19 an Endothelial Disease? A Comprehensive Evaluation of Clinical and Basic Evidence. J Clin Med. 2020;9:1417.10.3390/jcm9051417729076932403217Search in Google Scholar

4. Giannis D, Ziogas IA, Gianni P. Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past. J Clin Virol. 2020;127:104362.10.1016/j.jcv.2020.104362719527832305883Search in Google Scholar

5. Danzi GB, Loffi M, Galeazzi G, Gherbesi E. Acute pulmonary embolism and COVID-19 pneumonia: a random association?. Eur Heart J. 2020;41:1858.10.1093/eurheartj/ehaa254718440632227120Search in Google Scholar

6. ten Cate H. Thrombosis management in times of COVID-19 epidemy; a Dutch perspective. Thromb J. 2020;18:7.10.1186/s12959-020-00220-3716936932336956Search in Google Scholar

7. Conti P, Ronconi G, Caraffa A, et al. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. J Biol Regul Homeost Agents. 2020;34:327-331.Search in Google Scholar

8. Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost. 2020;18:1421-1424.10.1111/jth.14830726232432271988Search in Google Scholar

9. Qin C, Zhou L, Hu Z, et al. Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis. 2020;71:762-768.10.1093/cid/ciaa248710812532161940Search in Google Scholar

10. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18:844-847.10.1111/jth.14768716650932073213Search in Google Scholar

11. Han H, Yang L, Liu R, et al. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. Clin Chem Lab Med. 2020;58:1116-1120.10.1515/cclm-2020-018832172226Search in Google Scholar

12. Helms J, Tacquard C, Severac F, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020;46:1089-1098.10.1007/s00134-020-06062-xSearch in Google Scholar

13. Barrett CD, Moore HB, Yaffe MB, Moore EE. ISTH interim guidance on recognition and management of coagulopathy in COVID-19: A comment. J Thromb Haemost. 2020;18:2060-2063.10.1111/jth.14860Search in Google Scholar

14. Schmidt M, Horvath-Puho E, Thomsen RW, Smeeth L, Sørensen HT. Acute infections and venous thromboembolism. J Intern Med. 2012;271:608-618.10.1111/j.1365-2796.2011.02473.xSearch in Google Scholar

15. Iba T, Levy JH, Warkentin TE, et al. Diagnosis and management of sepsis-induced coagulopathy and disseminated intravascular coagulation. J Thromb Haemost. 2019;17:1989-1994.10.1111/jth.14578Search in Google Scholar

16. Beristain-Covarrubias N, Perez-Toledo M, Thomas MR, Henderson IR, Watson SP, Cunningham AF. Understanding Infection-Induced Thrombosis: Lessons Learned From Animal Models. Front Immunol. 2019;10:2569.10.3389/fimmu.2019.02569Search in Google Scholar

17. Semeraro N, Ammollo CT, Semeraro F, Colucci M. Sepsis, thrombosis and organ dysfunction. Thromb Res. 2012;129:290-295.10.1016/j.thromres.2011.10.013Search in Google Scholar

18. Fox SE, Akmatbekov A, Harbert JL, Li G, Quincy Brown J, Vander Heide RS. Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans. Lancet Respir Med. 2020;8:681-686.10.1016/S2213-2600(20)30243-5Search in Google Scholar

19. Spiezia L, Boscolo A, Poletto F, et al. COVID-19-Related Severe Hypercoagulability in Patients Admitted to Intensive Care Unit for Acute Respiratory Failure. Thromb Haemost. 2020;120:998-1000.10.1055/s-0040-171435032702757Search in Google Scholar

20. Klok FA, Kruip MJHA, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145-147.10.1016/j.thromres.2020.04.013714671432291094Search in Google Scholar

21. Kollias A, Kyriakoulis KG, Dimakakos E, Poulakou G, Stergiou GS, Syrigos K. Thromboembolic risk and anticoagulant therapy in COVID-19 patients: emerging evidence and call for action. Br J Haematol. 2020;189:846-847.10.1111/bjh.16727726453732304577Search in Google Scholar

22. Llitjos JF, Leclerc M, Chochois C, et al. High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. J Thromb Haemost. 2020;18:1743-1746.10.1111/jth.14869726477432320517Search in Google Scholar

23. Obi AT, Barnes GD, Wakefield TW, et al. Practical diagnosis and treatment of suspected venous thromboembolism during COVID-19 pandemic. J Vasc Surg Venous Lymphat Disord. 2020;8:526-534.10.1016/j.jvsv.2020.04.009716279432305585Search in Google Scholar

24. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020;18:1094-1099.10.1111/jth.1481732220112Search in Google Scholar